| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6168479 | Urology | 2011 | 5 Pages |
Abstract
Heat shock protein 90 inhibition with IPI-504 administered as a single agent had a minimal effect on the PSA level or tumor burden and was associated with unacceptable toxicity in several patients. Therefore, additional evaluation in CRPC patients is not warranted. IPI-504 is being investigated at less-intensive doses and schedules in other tumor types.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
William K. Oh, Matthew D. Galsky, Walter M. Stadler, Sandy Srinivas, Franklin Chu, Glenn Bubley, J. Goddard, Joi Dunbar, Robert W. Ross,